All Stories

ASCO: Innate claims long-term lymphoma data show 'sustained effect' of anti-KIR3DL2 antibody

Innate Pharma has produced long-term data showing that its anti-KIR3DL2 antibody has a “sustained effect” against two types of lymphoma.

May 23, 2025 - 12:10
 0
ASCO: Innate claims long-term lymphoma data show 'sustained effect' of anti-KIR3DL2 antibody
Innate Pharma has produced long-term data showing that its anti-KIR3DL2 antibody has a “sustained effect” against two types of lymphoma.
Read More

Tags:

Previous Article

V12 Sports and Classics boosts vehicle security with tracking tech

Next Article

Referral: Azithromycin-containing medicinal products for systemic use, azithromy...

Related Posts

Court extends block on HHS RIF after Trump's Supreme Court appeal

Court extends block on HHS RIF after Trump's Supreme Co...

May 23, 2025  0

Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8% of global workforce; NGM sheds 75% of staff

Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8...

May 12, 2025  0

GSK pays $1.2B upfront for Boston Pharmaceuticals’ lead liver disease drug

GSK pays $1.2B upfront for Boston Pharmaceuticals’ lead...

May 14, 2025  0